Renal Disorder Associated With Type II Diabetes Mellitus
Conditions
Brief summary
The study is to treat metformin dose-escalation diabetic subjects of all stages of renal failure (stages 1-5) and compare their rates of erythrocyte metformin (best reflections of a possible accumulation than those of plasma) to the therapeutic range. A number of 12 patients by stage is considered, 60 patients in total.
Interventions
DRUGMetformin
Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended: engaged during or at the end of the meal in the evening for the single dose 500 mg (Phase 1), the evening and morning for total doses of 1000 mg, 2000 mg and 3000 mg (with, respectively, 2 tab. 500 mg, 2 tab. to 1000 mg, 1 tab. to 1000 mg and 2 tab. to 1000 mg), a fourth dose is also scheduled to stage one (3000 mg / d)
Sponsors
Merck Serono International SA
Centre Hospitalier Universitaire, Amiens
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Diabetic patients not treated with metformin, no treatment diabetic or have been treated but poorly balanced (HbA1c\> 7%) and an applicant building with metformin; at any stage renal stable (stages 1-5 according to the classification MDRD) * Patients aged 18 to 80 years; * Patients with an assessment of renal function dating back more than 3 months; * Patients whose renal function is stable, on the criterion of the absence of fluctuation over 30% of renal function of creatinine clearance in the last three months, a reference to renal function at least 3 months from the balance sheet inclusion is necessary.
Exclusion criteria
* Patient over 80 years * Patients incapacitated adults (protected under guardianship) * No previous reference creatinine; * Fluctuation over 30% of renal function (creatinine clearance) in the three months; * Reduction in BMI of more than 5% during the last 3 months; * Severe hepatic impairment (Child stage\> A); * No reference to liver stages 3-5 * Patients to be an X-ray with injection of contrast.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the percentage of patients in each category of renal function whose rate of erythrocyte metformin remain within the therapeutic range, at each stage of treatment. | Phase 1 : Day 7 |
| the percentage of patients in stage 1 of chronic kidney disease (CKD) each category of renal function whose rate of erythrocyte metformin remain within the therapeutic range, at each stage of treatment. | Phase 4 : Day 49 |
Secondary
| Measure | Time frame |
|---|---|
| the percentage of patients in stages 3-5 of CKD each stage renal disease with a blood erythrocyte remaining within the therapeutic range or higher, and but without significative hyperlactatemia (≥ 2.5 mmol / l) in the latter case. | phase1 : Day 7 |
Countries
France
Outcome results
None listed